Form 10-Q · Quarterly report
Teledyne Technologies 10-Q, filed Jul 24, 2026
- Filed
- CIK
- 0001094285
- Accession no.
- 0001094285-26-000043
Summary
Teledyne Technologies reported second-quarter 2026 net sales of $1.66 billion, up 9.8% from a year earlier, and net income attributable to Teledyne of $251.7 million, or $5.37 per diluted share, up 19.9%. The company said higher sales and overall operating margin drove the increase, while it continued to manage tariff and rare-earth supply-chain risks.
Key points
- Second-quarter 2026 net sales rose in each of Teledyne's four segments; total net sales were $1,662.5 million, up 9.8% from the second quarter of 2025.
- Net income attributable to Teledyne was $251.7 million, or $5.37 per diluted share, compared with $209.9 million, or $4.43 per diluted share, a year earlier.
- Teledyne said the U.S. Supreme Court invalidated IEEPA tariffs in February 2026, that it filed for IEEPA refunds during the first half of 2026, and that it began receiving those refunds in the second quarter of 2026 while continuing to pay tariffs.
- Teledyne plans to invest approximately $150 million in capital expenditures during 2026 and continues facility consolidation, product rationalization, and headcount reductions.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview Teledyne provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability. These markets include aerospace and defense, factory automation, air and water quality environmental monitoring, electronics design and development, oceanographic research, deepwater oil and gas exploration and production, medical imaging, and pharmaceutical research. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.